公开(公告)号：US20230194549A1

公开(公告)日：2023-06-22

申请号：US17918184

申请日：2021-04-08

申请人： BIOMÉRIEUX ,  BIOASTER ,  HOSPICES CIVILS DE LYON

发明人： François MALLET ,  Guillaume MONNERET ,  Virginie MOUCADEL ,  Alexandre PACHOT ,  Estelle PERONNET ,  Julien TEXTORIS ,  Fabienne VENET ,  Thomas RIMMELÉ

IPC分类号： G01N33/68 ,  G01N33/569

CPC分类号： G01N33/6866 ,  G01N33/56938 ,  G01N2333/31 ,  G01N2333/52 ,  G01N2800/26 ,  G01N2800/50

摘要： An in vitro or ex vivo method, based on the measurement of the expression of cytokine(s), from a patient's blood sample, incubated with a stimulus, for determining the risk of occurrence of a healthcare-associated infection in the patient, within seven days following the day on which the collection of the biological sample has been performed from the patient.

公开(公告)号：US20220333201A1

公开(公告)日：2022-10-20

申请号：US17764323

申请日：2020-09-25

申请人： BIOMÉRIEUX ,  BIOASTER ,  HOSPICES CIVILS DE LYON

发明人： Laurence VACHOT ,  François MALLET ,  Guillaume MONNERET ,  Virginie MOUCADEL ,  Alexandre PACHOT ,  Estelle PERONNET ,  Thomas RIMMELÉ ,  Julien TEXTORIS ,  Fabienne VENET

IPC分类号： C12Q1/6883 ,  G16H50/30

摘要： An in vitro or ex vivo method for determining the risk of occurrence of a healthcare-associated infection in a patient, including a step of measuring the expression of CX3CR1, in a biological sample of said patient.

公开(公告)号：US20160195542A1

公开(公告)日：2016-07-07

申请号：US14916288

申请日：2014-09-18

申请人： BIOMÉRIEUX ,  HOSPICES CIVILS DE LYON

发明人： Guillaume MONNERET ,  Fabienne VENET ,  Alain LEPAPE ,  Julie DEMARET ,  Astrid VILLARS-MECHIN

IPC分类号： G01N33/68

摘要： The invention provides a method of evaluating the risk of mortality in patients who present a systemic inflammatory response (SIRS) or septic syndromes, comprising measuring the expression of sCD127 in a biological sample.

摘要翻译： 本发明提供了评估存在全身炎症反应（SIRS）或败血症综合征的患者的死亡风险的方法，包括测量生物样品中sCD127的表达。

公开(公告)号：US20160017423A1

公开(公告)日：2016-01-21

申请号：US14649803

申请日：2014-01-10

申请人： BIOMÉRIEUX ,  HOSPICES CIVILS DE LYON

发明人： Marie-Angelique CAZALIS ,  Maud TOURNOUD ,  Fabienne VENET ,  Alain LEPAPE ,  Guillaume MONNERET

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/26

摘要： The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.

摘要翻译： 本发明的主题是用于对脓毒性休克患者的严重程度进行体外预​​后的方法，包括以下步骤：（i）选自lilrb2和lilrb1的至少一种基因的表达产物的表达水平 基于从患者取得的生物样品在体外测量基因，（ii）将至少一种基因的表达产物的表达水平与相同表达产物的表达的对照水平进行比较 基因，具有良好的严重预后，其中低于对照表达水平的至少一种基因的表达产物的表达水平表示对患者的严重程度不良的预后，以及用于实施该方法的试剂盒。

公开(公告)号：US20180095094A1

公开(公告)日：2018-04-05

申请号：US15573499

申请日：2016-05-11

申请人： BIOMÉRIEUX ,  HOSPICES CIVILS DE LYON ,  CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

发明人： Bernard ALLAOUCHICHE ,  Karim ASEHNOUNE ,  Marilyne DUPIN ,  Tanguy FORTIN ,  Aurélie GOUEL-CHERON ,  Audrey LARUE-TRIOLET ,  Guillaume MONNERET ,  Alexandre PACHOT ,  Sylvie PONS ,  Antoine ROQUILLY ,  Fabienne VENET

IPC分类号： G01N33/68 ,  G01N33/53

摘要： A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from said patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from said patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a Δ value; and comparing the Δ value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

公开(公告)号：US20190017118A1

公开(公告)日：2019-01-17

申请号：US15780573

申请日：2016-12-01

申请人： BIOMERIEUX ,  HOSPICES CIVILS DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1

发明人： Elisabeth CERRATO ,  Benjamin DELWARDE ,  Guillaume MONNERET ,  Estelle PERONNET ,  Julien TEXTORIS ,  Fabienne VENET

IPC分类号： C12Q1/6883 ,  C12Q1/6806 ,  C12Q1/686

摘要： The invention concerns a method of in vitro or ex vivo evaluation of the risk of complications in a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, the method being characterized in that it comprises the step of detecting, in a biological sample obtained from said patient, at least one transcript of the IL7R gene, as well as measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene, in a biological sample from a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, in order to evaluate the risk of complications, and in particular of mortality, in said patient.The invention also concerns kits for measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene in a biological sample.

公开(公告)号：US20180312921A1

公开(公告)日：2018-11-01

申请号：US15960966

申请日：2018-04-24

申请人： BIOMERIEUX ,  HOSPICES CIVILS DE LYON (HCL)

发明人： Fanny DAVIN ,  Alain LEPAPE ,  Guillaume MONNERET ,  Florence FRAGER

IPC分类号： C12Q1/6876 ,  G01N33/68 ,  C12Q1/6883 ,  C40B30/04

CPC分类号： C12Q1/6876 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  C40B30/04 ,  G01N33/68

摘要： The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual.

公开(公告)号：US20220259661A1

公开(公告)日：2022-08-18

申请号：US17729115

申请日：2022-04-26

申请人： BIOMERIEUX ,  HOSPICES CIVILS DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1

发明人： Elisabeth CERRATO ,  Benjamin DELWARDE ,  Guillaume MONNERET ,  Estelle PERONNET ,  Julien TEXTORIS ,  Fabienne VENET

IPC分类号： C12Q1/6883 ,  C12Q1/6806 ,  C12Q1/686

摘要： A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.

公开(公告)号：US20180111342A1

公开(公告)日：2018-04-26

申请号：US15786755

申请日：2017-10-18

申请人： HOSPICES CIVILS DE LYON ,  BIOMERIEUX

发明人： Alain LEPAPE ,  Fabienne VENET ,  Astrid VILLARS ,  Guillaume MONNERET

IPC分类号： B29C70/38 ,  C08J5/24 ,  B29C70/54 ,  B29C35/02 ,  B29C70/16 ,  B29B15/08 ,  B29C53/58 ,  B29K101/10 ,  B29K105/24

CPC分类号： G01N33/54306 ,  B29B15/08 ,  B29C35/0266 ,  B29C53/582 ,  B29C70/16 ,  B29C70/384 ,  B29C70/54 ,  B29C2035/0211 ,  B29K2101/10 ,  B29K2105/243 ,  C08J5/24 ,  G01N33/53 ,  G01N33/6893 ,  G01N33/96 ,  G01N2333/7155 ,  G01N2800/26 ,  G01N2800/50

摘要： A kit for in vitro or ex vivo measurement of sCD127 expression in a biological sample, the kit including: specific tools or reagents allowing measurement of sCD127 expression in said biological sample; and a positive standard sample which is a sample calibrated to contain an amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known to have developed a nosocomial infection, and/or a negative standard sample which is a sample calibrated to contain the amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known not to have developed a nosocomial infection.

公开(公告)号：US20160052881A1

公开(公告)日：2016-02-25

申请号：US14781145

申请日：2014-04-04

申请人： UNIVERSITE CLAUDE BERNARD LYON I ,  HOSPICES CIVILS DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Charles DUMONTET ,  Ahcene BOUMENDJEL ,  Guillaume MONNERET

IPC分类号： C07D211/32

CPC分类号： C07D211/32 ,  C07D211/22

摘要： The present invention relates to the compounds of formula (I): wherein: R2, R4 and R6, either identical or different, represent a hydrogen, chlorine bromine, iodine or fluorine atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; R2′ and R4′, either identical or different, represent a hydrogen atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; with R2′ and/or R4′ which represent a methoxy group; n is equal to 1, 2, 3; X═CH2, O, S or N(R7); and R7 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; as well as pharmaceutically acceptable hydrates, solvates and salts thereof.

摘要翻译： 本发明涉及式（I）的化合物：其中：R 2，R 4和R 6相同或不同，代表氢，氯溴，碘或氟原子，或基团-OH或-O-烷基，包括 1至6个碳原子; R 2'和R 4'相同或不同，表示氢原子，或基团-OH或含有1至6个碳原子的-O-烷基; 其中R2'和/或R4'代表甲氧基; n等于1,2,3; X = CH 2，O，S或N（R 7）; 并且R 7表示氢原子或含有1至6个碳原子的烷基; 以及其药学上可接受的水合物，溶剂化物和盐。